{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T07:10:52Z","timestamp":1788765052654,"version":"build-2803163510"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,7]]},"DOI":"10.7759\/cureus.115878","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T07:03:52Z","timestamp":1788764632000},"source":"Crossref","is-referenced-by-count":0,"title":["Ranolazine in Chronic Stable Angina: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Peter","family":"Collins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Alhabeeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Alhaddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulhalim J","family":"Kinsara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid Al","family":"Faraidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Balghith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Ragy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafa","family":"Fehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iliyasse","family":"Asfalou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fakhr Al","family":"Ayoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duraid","family":"Al-Rammahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Batah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1527","article-title":"Diagnosis and management of stable angina: a review","volume":"325","author":"Joshi PH","year":"2021","unstructured":"Joshi PH, de Lemos JA. Diagnosis and management of stable angina: a review. JAMA. 2021, 325:1765-78. 10.1001\/jama.2021.1527","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-029661","article-title":"Functional status and life satisfaction of patients with stable angina pectoris in Austria","volume":"9","author":"Spinka F","year":"2019","unstructured":"Spinka F, Aichinger J, Wallner E, et al.. Functional status and life satisfaction of patients with stable angina pectoris in Austria. BMJ Open. 2019, 9:e029661. 10.1136\/bmjopen-2019-029661","journal-title":"BMJ Open"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2217\/fca-2021-0058","article-title":"Ranolazine: a better understanding of its pathophysiology and patient profile to guide treatment of chronic stable angina","volume":"18","author":"Tamargo J","year":"2022","unstructured":"Tamargo J, Lopez-Sendon J. Ranolazine: a better understanding of its pathophysiology and patient profile to guide treatment of chronic stable angina. Future Cardiol. 2022, 18:235-51. 10.2217\/fca-2021-0058","journal-title":"Future Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S4468","article-title":"Emerging clinical role of ranolazine in the management of angina","volume":"6","author":"Vadnais DS","year":"2010","unstructured":"Vadnais DS, Wenger NK. Emerging clinical role of ranolazine in the management of angina. Ther Clin Risk Manag. 2010, 6:517-30. 10.2147\/TCRM.S4468","journal-title":"Ther Clin Risk Manag"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.11.070","article-title":"The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials","volume":"113","author":"Banon D","year":"2014","unstructured":"Banon D, Filion KB, Budlovsky T, Franck C, Eisenberg MJ. The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials. Am J Cardiol. 2014, 113:1075-82. 10.1016\/j.amjcard.2013.11.070","journal-title":"Am J Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021, 88:105906. 10.1016\/j.ijsu.2021.105906","journal-title":"Int J Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/pra2.745","article-title":"Performance, usability, and user experience of Rayyan for systematic reviews","volume":"59","author":"Yu F","year":"2022","unstructured":"Yu F, Liu C, Sharmin S. Performance, usability, and user experience of Rayyan for systematic reviews. Proc Assoc Inf Sci Technol. 2022, 59:843-4. 10.1002\/pra2.745","journal-title":"Proc Assoc Inf Sci Technol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi S","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019, 22:153-60. 10.1136\/ebmental-2019-300117","journal-title":"Evid Based Ment Health"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Huedo-Medina TB","year":"2006","unstructured":"Huedo-Medina TB, S\u00e1nchez-Meca J, Mar\u00edn-Mart\u00ednez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index?. Psychol Methods. 2006, 11:193-206. 10.1037\/1082-989X.11.2.193","journal-title":"Psychol Methods"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphys.2014.06.021","article-title":"Forest plots","volume":"60","author":"Verhagen AP","year":"2014","unstructured":"Verhagen AP, Ferreira ML. Forest plots. J Physiother. 2014, 60:170-3. 10.1016\/j.jphys.2014.06.021","journal-title":"J Physiother"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.05.020","article-title":"Long-term (3 years) outcomes of ranolazine therapy for refractory angina pectoris (from the Ranolazine Refractory Registry)","volume":"129","author":"Storey KM","year":"2020","unstructured":"Storey KM, Wang J, Garberich RF, et al.. Long-term (3 years) outcomes of ranolazine therapy for refractory angina pectoris (from the Ranolazine Refractory Registry). Am J Cardiol. 2020, 129:1-4. 10.1016\/j.amjcard.2020.05.020","journal-title":"Am J Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.10.180","article-title":"Ranolazine reduces angina frequency and severity and improves quality of life: observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR)","volume":"205","author":"Alexopoulos D","year":"2016","unstructured":"Alexopoulos D, Kochiadakis G, Afthonidis D, et al.. Ranolazine reduces angina frequency and severity and improves quality of life: observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR). Int J Cardiol. 2016, 205:111-6. 10.1016\/j.ijcard.2015.10.180","journal-title":"Int J Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.36660\/abc.20210711","article-title":"Concomitant use of ranolazine and trimetazidine in patients with refractory angina: an initial experience","volume":"119","author":"Dourado LO","year":"2022","unstructured":"Dourado LO, Moreno CP, Grobe SF, Gowdak LH, Cesar LA. Concomitant use of ranolazine and trimetazidine in patients with refractory angina: an initial experience. Arq Bras Cardiol. 2022, 119:619-21. 10.36660\/abc.20210711","journal-title":"Arq Bras Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.02.045","article-title":"Effects of ivabradine and ranolazine in patients with microvascular angina pectoris","volume":"112","author":"Villano A","year":"2013","unstructured":"Villano A, Di Franco A, Nerla R, et al.. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. Am J Cardiol. 2013, 112:8-13. 10.1016\/j.amjcard.2013.02.045","journal-title":"Am J Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2019.05.063","article-title":"Effects of exercise training with and without ranolazine on peak oxygen consumption, daily physical activity, and quality of life in patients with chronic stable angina pectoris","volume":"124","author":"Willis LH","year":"2019","unstructured":"Willis LH, Slentz CA, Johnson JL, Kelly LS, Craig KP, Hoselton AL, Kraus WE. Effects of exercise training with and without ranolazine on peak oxygen consumption, daily physical activity, and quality of life in patients with chronic stable angina pectoris. Am J Cardiol. 2019, 124:655-60. 10.1016\/j.amjcard.2019.05.063","journal-title":"Am J Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.019768","article-title":"Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) trial","volume":"133","author":"Alexander KP","year":"2016","unstructured":"Alexander KP, Weisz G, Prather K, et al.. Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) trial. Circulation. 2016, 133:39-47. 10.1161\/CIRCULATIONAHA.115.019768","journal-title":"Circulation"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.08.002","article-title":"Comparative effectiveness of ranolazine versus traditional therapies in chronic stable angina pectoris and concomitant diabetes mellitus and impact on health care resource utilization and cardiac interventions","volume":"116","author":"Page RL 2nd","year":"2015","unstructured":"Page RL 2nd, Ghushchyan V, Read RA, Hartsfield CL, Koch BR 2nd, Nair KV. Comparative effectiveness of ranolazine versus traditional therapies in chronic stable angina pectoris and concomitant diabetes mellitus and impact on health care resource utilization and cardiac interventions. Am J Cardiol. 2015, 116:1321-8. 10.1016\/j.amjcard.2015.08.002","journal-title":"Am J Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.04.042","article-title":"The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease","volume":"56","author":"Stone PH","year":"2010","unstructured":"Stone PH, Chaitman BR, Stocke K, Sano J, DeVault A, Koch GG. The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease. J Am Coll Cardiol. 2010, 56:934-42. 10.1016\/j.jacc.2010.04.042","journal-title":"J Am Coll Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial","volume":"291","author":"Chaitman BR","year":"2004","unstructured":"Chaitman BR, Pepine CJ, Parker JO, et al.. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004, 291:309-16. 10.1001\/jama.291.3.309","journal-title":"JAMA"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2018.09.081","article-title":"Late sodium channel blockade improves angina and myocardial perfusion in patients with severe coronary microvascular dysfunction: Women's Ischemia Syndrome Evaluation-coronary vascular dysfunction ancillary study","volume":"276","author":"Rambarat CA","year":"2019","unstructured":"Rambarat CA, Elgendy IY, Handberg EM, et al.. Late sodium channel blockade improves angina and myocardial perfusion in patients with severe coronary microvascular dysfunction: Women's Ischemia Syndrome Evaluation-coronary vascular dysfunction ancillary study. Int J Cardiol. 2019, 276:8-13. 10.1016\/j.ijcard.2018.09.081","journal-title":"Int J Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.066680","article-title":"ChaMP-CMD: a phenotype-blinded, randomized controlled, cross-over trial","volume":"149","author":"Sinha A","year":"2024","unstructured":"Sinha A, Rahman H, Douiri A, et al.. ChaMP-CMD: a phenotype-blinded, randomized controlled, cross-over trial. Circulation. 2024, 149:36-47. 10.1161\/CIRCULATIONAHA.123.066680","journal-title":"Circulation"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2459\/JCM.0000000000000627","article-title":"Ranolazine treatment in the heterogeneous symptomatic stable coronary artery disease population","volume":"19","author":"Borzi M","year":"2018","unstructured":"Borzi M, Intorcia A, Perrone MA, Grilli G, Sergi D, Borzi M, Romeo F. Ranolazine treatment in the heterogeneous symptomatic stable coronary artery disease population. J Cardiovasc Med (Hagerstown). 2018, 19:186-90. 10.2459\/JCM.0000000000000627","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1080\/14779072.2021.1914589","article-title":"Antinociceptive effect of ranolazine and trimetazidine","volume":"19","author":"Tolunay H","year":"2021","unstructured":"Tolunay H. Antinociceptive effect of ranolazine and trimetazidine. Expert Rev Cardiovasc Ther. 2021, 19:457-64. 10.1080\/14779072.2021.1914589","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000779","article-title":"Ranolazine for symptomatic management of microvascular angina","volume":"27","author":"Rayner-Hartley E","year":"2020","unstructured":"Rayner-Hartley E, Parvand M, Humphries KH, Starovoytov A, Park JE, Sedlak T. Ranolazine for symptomatic management of microvascular angina. Am J Ther. 2020, 27:e151-8. 10.1097\/MJT.0000000000000779","journal-title":"Am J Ther"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.008204","article-title":"Microvascular assessment of ranolazine in non-obstructive atherosclerosis: the MARINA randomized, double-blinded, controlled pilot trial","volume":"13","author":"Koh JS","year":"2020","unstructured":"Koh JS, Hung OY, Eshtehardi P, et al.. Microvascular assessment of ranolazine in non-obstructive atherosclerosis: the MARINA randomized, double-blinded, controlled pilot trial. Circ Cardiovasc Interv. 2020, 13:e008204. 10.1161\/CIRCINTERVENTIONS.119.008204","journal-title":"Circ Cardiovasc Interv"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.06.003","article-title":"Ranolazine improves insulin resistance in non-diabetic patients with coronary heart disease. A pilot study","volume":"219","author":"Caminiti G","year":"2016","unstructured":"Caminiti G, Fossati C, Battaglia D, Massaro R, Rosano G, Volterrani M. Ranolazine improves insulin resistance in non-diabetic patients with coronary heart disease. A pilot study. Int J Cardiol. 2016, 219:127-9. 10.1016\/j.ijcard.2016.06.003","journal-title":"Int J Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2018.7019","article-title":"Ranolazine reduces angina in women with ischemic heart disease: results of an open-label, multicenter trial","volume":"28","author":"Mehta PK","year":"2019","unstructured":"Mehta PK, Sharma S, Minissian M, et al.. Ranolazine reduces angina in women with ischemic heart disease: results of an open-label, multicenter trial. J Womens Health (Larchmt). 2019, 28:573-82. 10.1089\/jwh.2018.7019","journal-title":"J Womens Health (Larchmt)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2017.04.012","article-title":"Impact of ranolazine on coronary microvascular dysfunction (MICRO) study","volume":"18","author":"Ahmed B","year":"2017","unstructured":"Ahmed B, Mondragon J, Sheldon M, Clegg S. Impact of ranolazine on coronary microvascular dysfunction (MICRO) study. Cardiovasc Revasc Med. 2017, 18:431-5. 10.1016\/j.carrev.2017.04.012","journal-title":"Cardiovasc Revasc Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.12.002","article-title":"Ranolazine and microvascular angina by PET in the emergency department: results from a pilot randomized controlled trial","volume":"39","author":"Safdar B","year":"2017","unstructured":"Safdar B, D'Onofrio G, Dziura J, Russell RR, Johnson C, Sinusas AJ. Ranolazine and microvascular angina by PET in the emergency department: results from a pilot randomized controlled trial. Clin Ther. 2017, 39:55-63. 10.1016\/j.clinthera.2016.12.002","journal-title":"Clin Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-019-1481-x","article-title":"Ranolazine: impact on quality of life in patients with stable angina pectoris, results from an observational study in Austria - the ARETHA\u00a0AT study","volume":"131","author":"Zweiker R","year":"2019","unstructured":"Zweiker R, Aichinger J, Metzler B, Lang I, Wallner E, Delle-Karth G. Ranolazine: impact on quality of life in patients with stable angina pectoris, results from an observational study in Austria - the ARETHA\u00a0AT study. Wien Klin Wochenschr. 2019, 131:165-73. 10.1007\/s00508-019-1481-x","journal-title":"Wien Klin Wochenschr"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2018.08.027","article-title":"Clinical and economic outcomes of ranolazine versus conventional antianginals users among veterans with chronic stable angina pectoris","volume":"122","author":"Bress AP","year":"2018","unstructured":"Bress AP, Dodson JA, King JB, et al.. Clinical and economic outcomes of ranolazine versus conventional antianginals users among veterans with chronic stable angina pectoris. Am J Cardiol. 2018, 122:1809-16. 10.1016\/j.amjcard.2018.08.027","journal-title":"Am J Cardiol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005027","article-title":"Ranolazine in symptomatic diabetic patients without obstructive coronary artery disease: impact on microvascular and diastolic function","volume":"6","author":"Shah NR","year":"2017","unstructured":"Shah NR, Cheezum MK, Veeranna V, et al.. Ranolazine in symptomatic diabetic patients without obstructive coronary artery disease: impact on microvascular and diastolic function. J Am Heart Assoc. 2017, 6:e005027. 10.1161\/JAHA.116.005027","journal-title":"J Am Heart Assoc"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.04.025","article-title":"Costs and clinical outcomes associated with use of ranolazine for treatment of angina","volume":"34","author":"Phelps CE","year":"2012","unstructured":"Phelps CE, Buysman EK, Gomez Rey G. Costs and clinical outcomes associated with use of ranolazine for treatment of angina. Clin Ther. 2012, 34:1395-407.e4. 10.1016\/j.clinthera.2012.04.025","journal-title":"Clin Ther"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00459-6","article-title":"Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Weisz G","year":"2016","unstructured":"Weisz G, G\u00e9n\u00e9reux P, I\u00f1iguez A, et al.. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016, 387:136-45. 10.1016\/S0140-6736(15)00459-6","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/echo.12674","article-title":"Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease","volume":"32","author":"Tagliamonte E","year":"2015","unstructured":"Tagliamonte E, Rigo F, Cirillo T, et al.. Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease. Echocardiography. 2015, 32:516-21. 10.1111\/echo.12674","journal-title":"Echocardiography"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2019.02.014","article-title":"Revascularization rates and associated costs in patients with stable ischemic heart disease initiating ranolazine versus traditional antianginals as add-on therapy","volume":"123","author":"Meyer N","year":"2019","unstructured":"Meyer N, Tran O, Hartsfield C, Nguyen L, Kazi DS, Koch B. Revascularization rates and associated costs in patients with stable ischemic heart disease initiating ranolazine versus traditional antianginals as add-on therapy. Am J Cardiol. 2019, 123:1602-9. 10.1016\/j.amjcard.2019.02.014","journal-title":"Am J Cardiol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh2016881233-40","article-title":"Triple antianginal combinations in the treatment of elderly and senile patients with stable angina (Article in Russian)","volume":"88","author":"Kanorskii SG","year":"2016","unstructured":"Kanorskii SG, Smolenskaya NV. Triple antianginal combinations in the treatment of elderly and senile patients with stable angina (Article in Russian). Ter Arkh. 2016, 88:33-40. 10.17116\/terarkh2016881233-40","journal-title":"Ter Arkh"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22425","article-title":"Effects of ranolazine in patients with chronic angina in patients with and without percutaneous coronary intervention for acute coronary syndrome: observations from the MERLIN-TIMI 36 trial","volume":"38","author":"Gutierrez JA","year":"2015","unstructured":"Gutierrez JA, Karwatowska-Prokopczuk E, Murphy SA, et al.. Effects of ranolazine in patients with chronic angina in patients with and without percutaneous coronary intervention for acute coronary syndrome: observations from the MERLIN-TIMI 36 trial. Clin Cardiol. 2015, 38:469-75. 10.1002\/clc.22425","journal-title":"Clin Cardiol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2011.06.001","article-title":"Ranolazine for the treatment of refractory angina in a veterans population","volume":"13","author":"Greene RS","year":"2012","unstructured":"Greene RS, Rangel RM, Edwards KL, et al.. Ranolazine for the treatment of refractory angina in a veterans population. Cardiovasc Revasc Med. 2012, 13:141.e1-5. 10.1016\/j.carrev.2011.06.001","journal-title":"Cardiovasc Revasc Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2011.03.007","article-title":"Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease","volume":"4","author":"Mehta PK","year":"2011","unstructured":"Mehta PK, Goykhman P, Thomson LE, et al.. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC Cardiovasc Imaging. 2011, 4:514-22. 10.1016\/j.jcmg.2011.03.007","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-013-0026-4","article-title":"Ranolazine reduces patient-reported angina severity and frequency and improves quality of life in selected patients with chronic angina","volume":"13","author":"Muhlestein JB","year":"2013","unstructured":"Muhlestein JB, Grehan S. Ranolazine reduces patient-reported angina severity and frequency and improves quality of life in selected patients with chronic angina. Drugs R D. 2013, 13:207-13. 10.1007\/s40268-013-0026-4","journal-title":"Drugs R D"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1097\/HPC.0000000000000022","article-title":"Ranolazine refractory angina registry: 1-year results","volume":"13","author":"Bennett NM","year":"2014","unstructured":"Bennett NM, Iyer V, Arndt TL, et al.. Ranolazine refractory angina registry: 1-year results. Crit Pathw Cardiol. 2014, 13:96-8. 10.1097\/HPC.0000000000000022","journal-title":"Crit Pathw Cardiol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.01.037","article-title":"Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial","volume":"53","author":"Wilson SR","year":"2009","unstructured":"Wilson SR, Scirica BM, Braunwald E, et al.. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol. 2009, 53:1510-6. 10.1016\/j.jacc.2009.01.037","journal-title":"J Am Coll Cardiol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1097\/MCA.0b013e32832a198b","article-title":"Ranolazine improves endothelial function in patients with stable coronary artery disease","volume":"20","author":"Deshmukh SH","year":"2009","unstructured":"Deshmukh SH, Patel SR, Pinassi E, et al.. Ranolazine improves endothelial function in patients with stable coronary artery disease. Coron Artery Dis. 2009, 20:343-7. 10.1097\/MCA.0b013e32832a198b","journal-title":"Coron Artery Dis"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eus400","article-title":"The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine","volume":"15","author":"Karwatowska-Prokopczuk E","year":"2013","unstructured":"Karwatowska-Prokopczuk E, Wang W, Cheng ML, Zeng D, Schwartz PJ, Belardinelli L. The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine. Europace. 2013, 15:429-36. 10.1093\/europace\/eus400","journal-title":"Europace"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q487","article-title":"Clinical experience with ranolazine in a veteran population with chronic stable angina","volume":"46","author":"Reeder DN","year":"2012","unstructured":"Reeder DN, Gillette MA, Franck AJ, Frohnapple DJ. Clinical experience with ranolazine in a veteran population with chronic stable angina. Ann Pharmacother. 2012, 46:42-50. 10.1345\/aph.1Q487","journal-title":"Ann Pharmacother"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13061672","article-title":"Real-world data from the use of ranolazine in patients with stable angina pectoris: the RANGER study","volume":"13","author":"Olympios C","year":"2024","unstructured":"Olympios C, Stafylas P, Dermitzakis A, et al.. Real-world data from the use of ranolazine in patients with stable angina pectoris: the RANGER study. J Clin Med. 2024, 13:1672. 10.3390\/jcm13061672","journal-title":"J Clin Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.4103\/jpp.JPP_168_16","article-title":"Antianginal efficacy and tolerability of ranolazine as an add-on drug to concomitant medications primarily metoprolol in chronic stable angina patients: a prospective, open-label study","volume":"8","author":"Khot AM","year":"2017","unstructured":"Khot AM, Anuradha HV, Prakash VS, Shivamurathy MC. Antianginal efficacy and tolerability of ranolazine as an add-on drug to concomitant medications primarily metoprolol in chronic stable angina patients: a prospective, open-label study. J Pharmacol Pharmacother. 2017, 8:21-7. 10.4103\/jpp.JPP_168_16","journal-title":"J Pharmacol Pharmacother"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S82288","article-title":"Ranolazine versus placebo in patients with ischemic cardiomyopathy and persistent chest pain or dyspnea despite optimal medical and revascularization therapy: randomized, double-blind crossover pilot study","volume":"11","author":"Shammas NW","year":"2015","unstructured":"Shammas NW, Shammas GA, Keyes K, Duske S, Kelly R, Jerin M. Ranolazine versus placebo in patients with ischemic cardiomyopathy and persistent chest pain or dyspnea despite optimal medical and revascularization therapy: randomized, double-blind crossover pilot study. Ther Clin Risk Manag. 2015, 11:469-74. 10.2147\/TCRM.S82288","journal-title":"Ther Clin Risk Manag"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2024.09.018","article-title":"Ranolazine effects on exercise tolerance and angina frequency in Taiwanese stable angina: a bridging study of the CARISA randomized trial","volume":"124","author":"Lee JK","year":"2025","unstructured":"Lee JK, Hsieh IC, Huang PH, et al.. Ranolazine effects on exercise tolerance and angina frequency in Taiwanese stable angina: a bridging study of the CARISA randomized trial. J Formos Med Assoc. 2025, 124:931-7. 10.1016\/j.jfma.2024.09.018","journal-title":"J Formos Med Assoc"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072110","article-title":"The role of ranolazine for the treatment of residual angina beyond the percutaneous coronary revascularization","volume":"9","author":"Calcagno S","year":"2020","unstructured":"Calcagno S, Infusino F, Salvi N, et al.. The role of ranolazine for the treatment of residual angina beyond the percutaneous coronary revascularization. J Clin Med. 2020, 9:2110. 10.3390\/jcm9072110","journal-title":"J Clin Med"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.2196\/39778","article-title":"Ranolazine versus allopurinol for eligible symptomatic patients with a history of angioplasty: comparative efficacy study","volume":"11","author":"Rahmani R","year":"2022","unstructured":"Rahmani R, Moradi Farsani E, Bahrami S. Ranolazine versus allopurinol for eligible symptomatic patients with a history of angioplasty: comparative efficacy study. Interact J Med Res. 2022, 11:e39778. 10.2196\/39778","journal-title":"Interact J Med Res"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1572364","article-title":"Ranolazine therapy reduces non-ST-segment-elevation myocardial infarction and unstable angina in coronary disease patients with angina","volume":"25","author":"Murray GL","year":"2016","unstructured":"Murray GL, Colombo J. Ranolazine therapy reduces non-ST-segment-elevation myocardial infarction and unstable angina in coronary disease patients with angina. Int J Angiol. 2016, 25:159-64. 10.1055\/s-0036-1572364","journal-title":"Int J Angiol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.2196\/resprot.8057","article-title":"Daily activity measured with wearable technology as a novel measurement of treatment effect in patients with coronary microvascular dysfunction: substudy of a randomized controlled crossover trial","volume":"6","author":"Birkeland K","year":"2017","unstructured":"Birkeland K, Khandwalla RM, Kedan I, et al.. Daily activity measured with wearable technology as a novel measurement of treatment effect in patients with coronary microvascular dysfunction: substudy of a randomized controlled crossover trial. JMIR Res Protoc. 2017, 6:e255. 10.2196\/resprot.8057","journal-title":"JMIR Res Protoc"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.107663","article-title":"Comparison of the efficacy and tolerability of ivabradine and ranolazine in patients of chronic stable angina pectoris","volume":"4","author":"Chaturvedi A","year":"2013","unstructured":"Chaturvedi A, Singh Y, Chaturvedi H, Thawani V, Singla S, Parihar D. Comparison of the efficacy and tolerability of ivabradine and ranolazine in patients of chronic stable angina pectoris. J Pharmacol Pharmacother. 2013, 4:33-8. 10.4103\/0976-500X.107663","journal-title":"J Pharmacol Pharmacother"},{"key":"ref58","article-title":"Comparative efficacy of trimetazidine and ranolazine in patients with angina","volume":"28","author":"Khalil-ur-Rehman","year":"2017","unstructured":"Khalil-ur-Rehman, Saeed MA, Gull T, Khalil MJ. Comparative efficacy of trimetazidine and ranolazine in patients with angina. Med Forum Mon. 2017, 28:59-62.","journal-title":"Med Forum Mon"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/BF00265967","article-title":"Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium","volume":"38","author":"Jain D","year":"1990","unstructured":"Jain D, Dasgupta P, Hughes LO, Lahiri A, Raftery EB. Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium. Eur J Clin Pharmacol. 1990, 38:111-4. 10.1007\/BF00265967","journal-title":"Eur J Clin Pharmacol"},{"key":"ref60","article-title":"Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem","volume":"20","author":"Cocco G","year":"1992","unstructured":"Cocco G, Rousseau MF, Bouvy T, Cheron P, Williams G, Detry JM, Pouleur H. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol. 1992, 20:131-8.","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref61","article-title":"Ranolazine, ethnicity and the metabolic syndrome (REMS) study: a pilot study showing differential effects amongst Caucasian, African American and Asians in exercise tolerance time and glycemic control","volume":"35","author":"Singh N","year":"2014","unstructured":"Singh N, Dubal P, Adams H, et al.. Ranolazine, ethnicity and the metabolic syndrome (REMS) study: a pilot study showing differential effects amongst Caucasian, African American and Asians in exercise tolerance time and glycemic control. Eur Heart J. 2014, 35:1199.","journal-title":"Eur Heart J"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1177\/2047487312450133","article-title":"Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial","volume":"19","author":"Send\u00f3n JL","year":"2012","unstructured":"Send\u00f3n JL, Lee S, Cheng ML, Ben-Yehuda O. Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial. Eur J Prev Cardiol. 2012, 19:952-9. 10.1177\/2047487312450133","journal-title":"Eur J Prev Cardiol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.90.2.726","article-title":"Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group","volume":"90","author":"Thadani U","year":"1994","unstructured":"Thadani U, Ezekowitz M, Fenney L, Chiang YK. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group. Circulation. 1994, 90:726-34. 10.1161\/01.cir.90.2.726","journal-title":"Circulation"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.011","article-title":"Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina)","volume":"61","author":"Kosiborod M","year":"2013","unstructured":"Kosiborod M, Arnold SV, Spertus JA, et al.. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol. 2013, 61:2038-45. 10.1016\/j.jacc.2013.02.011","journal-title":"J Am Coll Cardiol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.05.044","article-title":"Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial","volume":"48","author":"Stone PH","year":"2006","unstructured":"Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006, 48:566-75. 10.1016\/j.jacc.2006.05.044","journal-title":"J Am Coll Cardiol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.09.025","article-title":"Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris","volume":"95","author":"Rousseau MF","year":"2005","unstructured":"Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 2005, 95:311-6. 10.1016\/j.amjcard.2004.09.025","journal-title":"Am J Cardiol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.16.1775","article-title":"Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial","volume":"297","author":"Morrow DA","year":"2007","unstructured":"Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al.. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007, 297:1775-83. 10.1001\/jama.297.16.1775","journal-title":"JAMA"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.10.067","article-title":"Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE)","volume":"49","author":"Koren MJ","year":"2007","unstructured":"Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol. 2007, 49:1027-34. 10.1016\/j.jacc.2006.10.067","journal-title":"J Am Coll Cardiol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2009.09.006","article-title":"A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images","volume":"2","author":"Venkataraman R","year":"2009","unstructured":"Venkataraman R, Belardinelli L, Blackburn B, Heo J, Iskandrian AE. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images. JACC Cardiovasc Imaging. 2009, 2:1301-9. 10.1016\/j.jcmg.2009.09.006","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-308066.24","article-title":"24 short-term effectiveness and safety profile of Ranolazine in patients with refractory angina","volume":"101","author":"Patel P","year":"2015","unstructured":"Patel P, Yau C, Thapar S, Foley J, Khan M, Sainsbury P. 24 short-term effectiveness and safety profile of Ranolazine in patients with refractory angina. Heart. 2015, 101:A13-4. 10.1136\/heartjnl-2015-308066.24","journal-title":"Heart"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2022.06.796","article-title":"Physical activity and cardiac arrhythmias in patients with INOCA on the management with ranolazine","volume":"355","author":"Pylova T","year":"2022","unstructured":"Pylova T, Tseluyko V. Physical activity and cardiac arrhythmias in patients with INOCA on the management with ranolazine. Atherosclerosis. 2022, 355:197-8. 10.1016\/j.atherosclerosis.2022.06.796","journal-title":"Atherosclerosis"},{"key":"ref72","article-title":"Left ventricular diastolic function changes in patients with chronic stable angina pectoris in using ranolazine","volume":"20","author":"Kuchmin AA","year":"2018","unstructured":"Kuchmin AA, Epelshtein YV, Epelshtein DY, Shevelev AA, Shulenin SN. Left ventricular diastolic function changes in patients with chronic stable angina pectoris in using ranolazine. Eur J Heart Fail. 2018, 20:308.","journal-title":"Eur J Heart Fail"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-013-0038-z","article-title":"Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris","volume":"13","author":"Ling H","year":"2013","unstructured":"Ling H, Packard KA, Burns TL, Hilleman DE. Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris. Am J Cardiovasc Drugs. 2013, 13:407-12. 10.1007\/s40256-013-0038-z","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(19)30749-1","article-title":"Effect of ranolazine on activity level in patients with angina after fractional flow reserve based deferred intervention","volume":"73","author":"Malhotra A","year":"2019","unstructured":"Malhotra A, Cheema Y, Patel D, et al.. Effect of ranolazine on activity level in patients with angina after fractional flow reserve based deferred intervention. J Am Coll Cardiol. 2019, 73:141. 10.1016\/S0735-1097(19)30749-1","journal-title":"J Am Coll Cardiol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(18)30638-7","article-title":"The impact of ranolazine versus placebo on health related quality of life in patients with chronic stable angina and type 2 diabetes","volume":"71","author":"Coleman CI","year":"2018","unstructured":"Coleman CI, Nguyen E, Weeda ER, Kohn C. The impact of ranolazine versus placebo on health related quality of life in patients with chronic stable angina and type 2 diabetes. J Am Coll Cardiol. 2018, 71:A97. 10.1016\/S0735-1097(18)30638-7","journal-title":"J Am Coll Cardiol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-016-0081-3","article-title":"Improvement of subjective well-being by ranolazine in patients with chronic angina and known myocardial ischemia (imwell study)","volume":"6","author":"Bavry AA","year":"2017","unstructured":"Bavry AA, Park KE, Choi CY, Mahmoud AN, Wen X, Elgendy IY. Improvement of subjective well-being by ranolazine in patients with chronic angina and known myocardial ischemia (imwell study). Cardiol Ther. 2017, 6:81-8. 10.1007\/s40119-016-0081-3","journal-title":"Cardiol Ther"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv647","article-title":"A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve","volume":"37","author":"Bairey Merz CN","year":"2016","unstructured":"Bairey Merz CN, Handberg EM, Shufelt CL, et al.. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. Eur Heart J. 2016, 37:1504-13. 10.1093\/eurheartj\/ehv647","journal-title":"Eur Heart J"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.5812\/acvi.58285","article-title":"Noninvasive assessment of coronary flow reserve before and after ranolazine administration: does it improve in our real patients?","volume":"5","author":"Egea-Serrano P","year":"2018","unstructured":"Egea-Serrano P, Vidal-Garcia A, Montalban-Larrea S, Pelaez AI, Castilla A. Noninvasive assessment of coronary flow reserve before and after ranolazine administration: does it improve in our real patients?. Arch Cardiovasc Imaging. 2018, 5:1. 10.5812\/acvi.58285","journal-title":"Arch Cardiovasc Imaging"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi495","article-title":"Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes","volume":"27","author":"Timmis AD","year":"2006","unstructured":"Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J. 2006, 27:42-8. 10.1093\/eurheartj\/ehi495","journal-title":"Eur Heart J"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.11.045","article-title":"Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina","volume":"43","author":"Chaitman BR","year":"2004","unstructured":"Chaitman BR, Skettino SL, Parker JO, et al.. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004, 43:1375-82. 10.1016\/j.jacc.2003.11.045","journal-title":"J Am Coll Cardiol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(99)00190-3","article-title":"A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents","volume":"84","author":"Pepine CJ","year":"1999","unstructured":"Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am J Cardiol. 1999, 84:46-50. 10.1016\/s0002-9149(99)00190-3","journal-title":"Am J Cardiol"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2022.10","article-title":"Efficacy of ranolazine to improve diastolic performance in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"18","author":"Cempaka Putri DK","year":"2023","unstructured":"Cempaka Putri DK, Andrianto A, Al-Farabi MJ, Saputra PB, Nugraha RA. Efficacy of ranolazine to improve diastolic performance in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Eur Cardiol. 2023, 18:e02. 10.15420\/ecr.2022.10","journal-title":"Eur Cardiol"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1016\/j.hjc.2022.12.002","article-title":"Effects of ranolazine on various outcomes in patients with stable angina: an updated meta-analysis","volume":"71","author":"Manolis A","year":"2023","unstructured":"Manolis A, Kallistratos M, Poulimenos L, Zamfir T, Thomopoulos C. Effects of ranolazine on various outcomes in patients with stable angina: an updated meta-analysis. Hellenic J Cardiol. 2023, 71:26-32. 10.1016\/j.hjc.2022.12.002","journal-title":"Hellenic J Cardiol"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.08.131","article-title":"Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis","volume":"169","author":"Savarese G","year":"2013","unstructured":"Savarese G, Rosano G, D'Amore C, et al.. Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis. Int J Cardiol. 2013, 169:262-70. 10.1016\/j.ijcard.2013.08.131","journal-title":"Int J Cardiol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011747.pub2","article-title":"Ranolazine for stable angina pectoris","volume":"2","author":"Salazar CA","year":"2017","unstructured":"Salazar CA, Basilio Flores JE, Veramendi Espinoza LE, Mejia Dolores JW, Rey Rodriguez DE, Loza Mun\u00e1rriz C. Ranolazine for stable angina pectoris. Cochrane Database Syst Rev. 2017, 2:CD011747. 10.1002\/14651858.CD011747.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.21037\/qims-23-1029","article-title":"Ranolazine for improving coronary microvascular function in patients with nonobstructive coronary artery disease: a systematic review and meta-analysis with a trial sequential analysis of randomized controlled trials","volume":"14","author":"Ling H","year":"2024","unstructured":"Ling H, Fu S, Xu M, et al.. Ranolazine for improving coronary microvascular function in patients with nonobstructive coronary artery disease: a systematic review and meta-analysis with a trial sequential analysis of randomized controlled trials. Quant Imaging Med Surg. 2024, 14:1451-65. 10.21037\/qims-23-1029","journal-title":"Quant Imaging Med Surg"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjco.2020.09.005","article-title":"Efficacy of ranolazine for treatment of coronary microvascular dysfunction-a systematic review and meta-analysis of randomized trials","volume":"3","author":"Kofler T","year":"2021","unstructured":"Kofler T, Hess S, Moccetti F, et al.. Efficacy of ranolazine for treatment of coronary microvascular dysfunction-a systematic review and meta-analysis of randomized trials. CJC Open. 2021, 3:101-8. 10.1016\/j.cjco.2020.09.005","journal-title":"CJC Open"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017747901","article-title":"Efficacy and safety of ranolazine in diabetic patients: a systematic review and meta-analysis","author":"Zeng X","year":"2017","unstructured":"Zeng X, Zhang Y, Lin J, Zheng H, Peng J, Huang W. Efficacy and safety of ranolazine in diabetic patients: a systematic review and meta-analysis. Ann Pharmacother. 2017, 1060028017747901. 10.1177\/1060028017747901","journal-title":"Ann Pharmacother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/517396-ranolazine-in-chronic-stable-angina-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T07:03:53Z","timestamp":1788764633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/517396-ranolazine-in-chronic-stable-angina-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":88,"URL":"https:\/\/doi.org\/10.7759\/cureus.115878","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,7]]}}}